Spero Therapeutics Total Revenue

Spero Therapeutics (SPRO) currently reports a total revenue of $45M as of June 2026. That compares with $41M in the prior-year period — up 12.0% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Spero Therapeutics's total revenue history and peer comparisons.

Spero Therapeutics's total revenue increased from $41M to $45M — a 12.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Spero Therapeutics's total revenue of $45M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Spero Therapeutics reported $45M in total revenue as of June 2026. That compares with $41M in the prior-year period — up 12.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $45M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Spero Therapeutics, and consider following SPRO for alerts when major investors trade the stock.